
Overview
Teva Pharmaceuticals Polska supplies generic and specialty medicines and manufactures medicines in Krakow. The company runs educational campaigns about migraine and a contest supporting nonprofit initiatives in healthcare.
Financials
Revenue history (in m)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 84 days for 2021). 5 of 6 audited by a statutory auditor.
- 202513/08/2026
- 202404/07/2025
- 202308/07/2024
- 202211/07/2023
- 202107/10/2022
- 202012/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
- Advertising agencies (73.11.Z) Primary
Offer
- Generic medicines
- Specialty medicines
- Asthma medicines
- Migraine medicines
- Oncology medicines
Websites
The company has 8 websites. Traffic on the sites is measured with Google Analytics.
- teva.plLeki generyczne i specjalistyczne | firma farmaceutyczna TevaGoogle Tag ManagerCloudflare
- aviomarin.com.plAviomarin, dimenhydraminaGoogle Tag ManagerCloudflare
- calperos.plCalperos PLGoogle Tag ManagerCloudflare
Trademarks
The company holds 17 active trademarks registered with the Polish Patent Office. 80 marks have expired or were not registered. The first mark was filed in 1995.
| Mark | Protected until | |
|---|---|---|
| PRONASAL CONTROL (word) | Jun 3, 2029 | |
| APRESIA (word) | Feb 8, 2028 | |
| CO-BESPRES PLUS (word) | Sep 13, 2027 | |
| SAMODZIELNI Program wsparcia i opieki nad pacjentami chorymi na stwardnienie rozsiane | Aug 26, 2036 | |
| PRONASAL (word) | Aug 1, 2033 |
Job offers
The company has its own careers page: teva.pl/youcareer.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, joint action by two members of the management board, or by one member of the management board jointly with a commercial proxy, is required.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Pliva Hrvatska D.o.o. | 1,000 | $270,124.26 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2003-07-30.
35 1030 1508 0000 0008 0320 9006
91 1030 1508 0000 0008 0320 9065
69 1030 1508 0000 0008 0320 9073
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 49,344PLN 49,344 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 14, 2016 | Merger plan | |
| Jan 18, 2016 | Commercial Companies Code notice | |
| Nov 4, 2015 | Merger plan |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fresenius Kabi Polska sp. z o.o. | $247,097,438.47 | fresenius-kabi.com | ||
| Zentiva Polska sp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o. | $102,266,019.67 | lekam.pl | ||
| Farmak International sp. z o.o. | $101,647,142.16 | farmakinternational.pl | ||
| Sandoz Polska sp. z o.o. | $89,136,265.74 | sandoz.com | ||
| Orifarm Manufacturing Poland sp. z o.o. | $83,999,052.46 | orifarm.com | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| Aristo Pharma sp. z o.o. | $22,775,627.72 | aristo-pharma.pl |
FAQ
Last updated: 2026-10-07